UBS Group
BCTXZ

UBS Group’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

UBS Group’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$658 Buy
4,697
+4,692
+93,840% +$787 ﹤0.01% 9797
2025
Q4 		$1 Sell
5
-61
-92% -$23 ﹤0.01% 10433
2025
Q3 		$22 Sell
66
-1,123
-94% -$372 ﹤0.01% 10126
2025
Q2 		$1.26K Buy
+1,189
New +$1.28K ﹤0.01% 9649

Other funds holding BCTXZ

EAM
Empery Asset Management New York $83M AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS Group's BCTXZ Position: Q1 2026 in Review

UBS Group increased its BriaCell Therapeutics Corp Warrant (BCTXZ) stake by 93,840% in Q1 2026, buying an estimated $787 and bringing the position to 4,697 shares worth $658. The position accounts for ﹤0.01% of the portfolio, ranked #9797.

UBS Group first reported a position in BCTXZ in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.26K in Q2 2025. 4 funds tracked by Wall St. Rank hold BCTXZ as of Q1 2026.

  • UBS Group held 4,697 shares of BriaCell Therapeutics Corp Warrant worth $658 as of Q1 2026.
  • UBS Group bought 4,692 BriaCell Therapeutics Corp Warrant shares in Q1 2026, an estimated $787.
  • BriaCell Therapeutics Corp Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9797 holding.
  • UBS Group first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2025 and has held it in 4 quarters since.
  • UBS Group's BriaCell Therapeutics Corp Warrant position peaked at $1.26K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.